Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?

por Steenbruggen, Tessa G, Linn, Sabine C, Rodenhuis, Sjoerd, Sonke, Gabe S
Publicado 2015

Survival and prognostic factors in oligometastatic breast cancer

por van Ommen-Nijhof, Annemiek, Steenbruggen, Tessa G., Capel, Laura, Vergouwen, Michel, Vrancken Peeters, Marie-Jeanne T., Wiersma, Terry G., Sonke, Gabe S.
Publicado 2022

Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation

por de Jong, Vincent M. T., Pruntel, Roelof, Steenbruggen, Tessa G., Bleeker, Fonnet E., Nederlof, Petra, Hogervorst, Frans B. L., linn, Sabine C.
Publicado 2022

Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer

por Steenbruggen, Tessa G, Schaapveld, Michael, Horlings, Hugo M, Sanders, Joyce, Hogewoning, Sander J, Lips, Esther H, Vrancken Peeters, Marie-Jeanne T, Kok, Niels F, Wiersma, Terry, Esserman, Laura, van ‘t Veer, Laura J, Linn, Sabine C, Siesling, Sabine, Sonke, Gabe S
Publicado 2021

Myocardial dysfunction in long‐term breast cancer survivors treated at ages 40–50 years

por Jacobse, Judy N., Steggink, Lars C., Sonke, Gabe S., Schaapveld, Michael, Hummel, Yoran M., Steenbruggen, Tessa G., Lefrandt, Joop D., Nuver, Janine, Crijns, Anne P.G., Aleman, Berthe M.P., van der Meer, Peter, Gietema, Jourik A., van Leeuwen, Flora E.
Publicado 2019

The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction

por Bouwer, Nathalie I., Steenbruggen, Tessa G., Rier, Hánah N., Kitzen, Jos J. E. M., Smorenburg, Carolien H., van Bekkum, Marlies L., de Jong, Paul C., Drooger, Jan C., Holterhues, Cynthia, Kofflard, Marcel J. M., Boersma, Eric, Sonke, Gabe S., Levin, Mark‐David, Jager, Agnes
Publicado 2022

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast ca...

por Steenbruggen, Tessa G., Wolf, Denise M., Campbell, Michael J., Sanders, Joyce, Cornelissen, Sten, Thijssen, Bram, Salgado, Roberto A., Yau, Christina, O-Grady, Nick, Basu, Amrita, Bhaskaran, Rajith, Mittempergher, Lorenza, Hirst, Gillian L., Coppe, Jean-Philippe, Kok, Marleen, Sonke, Gabe S., van ‘t Veer, Laura J., Horlings, Hugo M.
Publicado 2023

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

por Bouwer, N. I., Steenbruggen, T. G., van Rosmalen, J., Rier, H. N., Kitzen, J. J. E. M., van Bekkum, M. L., Tije, A. J. Ten, de Jong, P. C., Drooger, J. C., Holterhues, C., Smorenburg, C. H., Kofflard, M. J. M., Boersma, E., Sonke, G. S., Levin, M.-D., Jager, A.
Publicado 2021

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

por Yau, Christina, Osdoit, Marie, van der Noordaa, Marieke, Shad, Sonal, Wei, Jane, de Croze, Diane, Hamy, Anne-Sophie, Laé, Marick, Reyal, Fabien, Sonke, Gabe S, Steenbruggen, Tessa G, van Seijen, Maartje, Wesseling, Jelle, Martín, Miguel, del Monte-Millán, Maria, López-Tarruella, Sara, Boughey, Judy C, Goetz, Matthew P, Hoskin, Tanya, Gould, Rebekah, Valero, Vicente, Edge, Stephen B, Abraham, Jean E, Bartlett, John M S, Caldas, Carlos, Dunn, Janet, Earl, Helena, Hayward, Larry, Hiller, Louise, Provenzano, Elena, Sammut, Stephen-John, Thomas, Jeremy S, Cameron, David, Graham, Ashley, Hall, Peter, Mackintosh, Lorna, Fan, Fang, Godwin, Andrew K, Schwensen, Kelsey, Sharma, Priyanka, DeMichele, Angela M, Cole, Kimberly, Pusztai, Lajos, Kim, Mi-Ok, van ‘t Veer, Laura J, Esserman, Laura J, Symmans, W Fraser
Publicado 2022